FDA Approves First BCL2 Drug for Lymphoma Patients

The FDA just approved Beqalzi, the first BCL2 inhibitor for patients with relapsed mantle cell lymphoma who've tried other treatments.

Over half the patients in trials responded to the new therapy, offering fresh hope for those with limited options.